ERRFI1 and neoplasm: Signal attenuation and downregulation of RTK pathways provide important implications in cancer therapeutics and several well characterized negative regulators in RTK signaling (such as PTEN, LRIG1 and ERRFI1) are bona fide tumor suppressors [172–174].